Gene · 2175
Papers3,803
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,001 to 1,020 of 3,803
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. | Cancers (Basel) | 2022 | 35267561 | PubTator, text mining | PubMed |
| Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. | Cancers (Basel) | 2022 | 35267504 | PubTator, text mining | PubMed |
| Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients. | Front Oncol | 2022 | 35251954 | PubTator, text mining | PubMed |
| Sequencing of BRCA1/2-alterations using NGS-based technology: annotation as a challenge. | Oncotarget | 2022 | 35251494 | PubTator, text mining | PubMed |
| Periocular subcutaneous granuloma annulare in a child: A case report. | Am J Ophthalmol Case Rep | 2022 | 35243130 | PubTator, text mining | PubMed |
| Case Report: A BRCA2 Mutation Identified Through Next-Generation Sequencing in a Birt-Hogg-Dubè Syndrome Family. | Front Oncol | 2022 | 35237525 | PubTator, text mining | PubMed |
| PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. | Onco Targets Ther | 2022 | 35237050 | PubTator, text mining | PubMed |
| Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. | EBioMedicine | 2022 | 35231699 | PubTator, text mining | PubMed |
| Heterozygous FMN2 missense variant found in a family case of premature ovarian insufficiency. | J Ovarian Res | 2022 | 35227295 | PubTator, text mining | PubMed |
| Cancer Incidence in the Kurdistan Region of Iraq: Results of a Seven-Year Cancer Registration in Erbil and Duhok Governorates. | Asian Pac J Cancer Prev | 2022 | 35225473 | PubTator, text mining | PubMed |
| Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer - Narrowing the Gap Between Bench and Bedside. | Front Immunol | 2022 | 35222436 | PubTator, text mining | PubMed |
| Fanconi Anemia Patients from an Indigenous Community in Mexico Carry a New Founder Pathogenic Variant in FANCG. | Int J Mol Sci | 2022 | 35216452 | PubTator, text mining | PubMed |
| Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. | Cancer Manag Res | 2022 | 35210863 | PubTator, text mining | PubMed |
| Diagnosis and Treatment of Primary Inflammatory Choriocapillaropathies (PICCPs): A Comprehensive Overview. | Medicina (Kaunas) | 2022 | 35208488 | PubTator, text mining | PubMed |
| Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. | Cancers (Basel) | 2022 | 35205662 | PubTator, text mining | PubMed |
| PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming? | Cancers (Basel) | 2022 | 35205654 | PubTator, text mining | PubMed |
| Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. | Cancers (Basel) | 2022 | 35205643 | PubTator, text mining | PubMed |
| Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics. | Diagnostics (Basel) | 2022 | 35204416 | PubTator, text mining | PubMed |
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. | Biomedicines | 2022 | 35203446 | PubTator, text mining | PubMed |
| Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes. | Biomedicines | 2022 | 35203410 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2175/papers?page=51